AbRegen

Therapeutic antibodies for regenerative medicine.

Flightless I

A negative regulator of wound healing. The Flii antibody technology has applications in non-healing chronic wounds, burn injuries, cancer and fragile skin disorders.

Development Program

AbRegen is currently focussed on an antibody-based therapy for Epidermolysis Bullosa.

Research Papers

Flii antibody technology has been validated in preclinical models of wound healing, fibrosis and cancer. 

Flightless I Technology

Flightless I is a novel drug target that regulates important cellular behaviours including mobility, contraction, adhesion, proliferation and cytokine production.  The activity of Flightless I is mediated through interaction with components of the cell’s cytoskeleton, modulation of intracellular signalling pathways and regulation of cellular transcription events.

Flightless I is a negative regulator of the migratory and proliferative events of tissue repair.  Inhibition of Flightless I using antibodies has been shown to improve wound repair in murine and porcine models of normal and compromised wound healing and a murine model of Epidermolysis Bullosa.

In addition, anti-flightless antibodies have been shown to reduce the incidence and growth of skin tumours in a mouse model of squamous cell carcinoma.

AbRegen Board and Management

Professor Allison Cowin

Founder, Chief Scientific Officer and Board Member

Dr Prashanth Rajan

Operations Manager

Dr Viraj Perera

Non-executive Board Member

Dr David Belford

Chairman of the Board

Therapeutic antibodies for regenerative medicine.

AbRegen is a preclinical stage biotechnology company that specialises in the development of antibody-based therapeutics for tissue repair applications.